Arbutus Biopharma Logo
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
October 01, 2024 07:30 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its...
Arbutus Biopharma Logo
Arbutus to Participate in Two Upcoming Investor Conferences
September 03, 2024 07:30 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...
Arbutus Biopharma Logo
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 01, 2024 07:30 ET | Arbutus Biopharma Corporation
End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a HBV functional cure treatment regimen IM-PROVE I...
Arbutus Biopharma Logo
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
July 18, 2024 07:30 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a...
Arbutus Biopharma Logo
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
June 06, 2024 11:15 ET | Arbutus Biopharma Corporation
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation...
Arbutus Biopharma Logo
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
June 05, 2024 02:30 ET | Arbutus Biopharma Corporation
At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were...
Arbutus Biopharma Logo
Arbutus to Participate in Jefferies Global Healthcare Conference
May 29, 2024 07:30 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a...
Arbutus Biopharma Logo
Arbutus to Present Imdusiran Data at EASL Congress 2024
May 22, 2024 02:00 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...
Arbutus Biopharma Logo
Arbutus to Participate in Two Upcoming Investor Conferences
May 07, 2024 07:30 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a...
Arbutus Biopharma Logo
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 02, 2024 07:30 ET | Arbutus Biopharma Corporation
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001...